Receptos Announces Pricing of Initial Public Offering of Common Stock
09 May 2013 - 9:02AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced the pricing of its initial
public offering of 5,200,000 shares of its common stock at an
initial public offering price of $14.00 per share. The shares of
Receptos' common stock are expected to begin trading on the Nasdaq
Global Market under the symbol "RCPT" on May 9, 2013. All of the
shares of common stock are being offered by Receptos. In addition,
Receptos has granted the underwriters a 30-day option to purchase
up to an additional 780,000 shares of common stock to cover
over-allotments, if any. The offering is expected to close on May
14, 2013, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO
Capital Markets are acting as joint book-running managers for the
offering. Wedbush PacGrow Life Sciences is acting as a
co-manager.
A registration statement relating to these securities was
declared effective by the Securities and Exchange
Commission on May 8, 2013. The offering is being made only by
means of a prospectus. Copies of the prospectus relating to the
offering may be obtained from Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, One Madison Avenue, New York, NY
10010, Telephone: (800) 221-1037, Email:
newyork.prospectus@credit-suisse.com; from Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, Telephone: (800) 808-7525, Email:
syndicate@leerink.com; or from BMO Capital Markets, Attention:
Equity Syndicate Department, 3 Times Square, New York, NY 10036,
Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024